false
0001771706
A1
0001771706
2025-12-19
2025-12-19
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 19, 2025
VIREO GROWTH INC.
(Exact name of registrant as specified in its
charter)
British Columbia
(State or other jurisdiction of Incorporation)
| 000-56225 |
|
82-3835655 |
| (Commission File Number) |
|
(IRS Employer Identification No.) |
| |
|
|
|
207 South 9th Street
Minneapolis, Minnesota |
|
55402 |
| (Address of principal executive offices) |
|
(Zip Code) |
(612) 999-1606
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 3.02 | Unregistered Sales of Equity Securities |
The information set forth below under Item 8.01
of this Current Report on Form 8-K related to the Shares (as defined below) to be issued in connection with the acquisition of the Notes
(as defined below) is incorporated herein by reference, to the extent required herein. The Shares are being issued in reliance upon the
exemptions from registration under the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2)
of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act.
| Item 7.01 | Regulation FD Disclosure |
On December 19, 2025, Vireo Growth Inc. (the “Company”)
issued a press release announcing the matters disclosed in this Current Report on Form 8-K, which is attached as Exhibit 99.1 hereto and
is incorporated herein solely for purposes of this Item 7.01 disclosure.
Pursuant to the rules and regulations of the Securities
and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1, and information set forth therein, is deemed
to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended.
On December 19, 2025, the Company entered into
Convertible Note Secondary Sale and Purchase Agreements (the “Note Purchase Agreements”) with certain holders (the “Noteholders”)
of those certain 13% Senior Secured Convertible Notes due December 7, 2026 (the “Notes”) of Medicine Man Technologies, Inc.
d/b/a Schwazze, a Nevada corporation (“Schwazze”). The Notes, which have a value of approximately $2,600,000, consisting of
principal and accrued interest, are being acquired for total consideration of approximately $1,600,000. The Notes to be purchased by the
Company will bring the Company’s percentage ownership of the total outstanding 13% Senior Secured Convertible Notes due December
7, 2026 to approximately 89%. The consideration will be paid in the form of the Company’s subordinate voting shares at closing at
a deemed price per share of $0.54 (the “Shares”). The purchases are expected to close by December 31, 2025, and are subject
to approval by the Canadian Stock Exchange.
The Notes accrue interest at a rate equal to 13%
per annum. Interest on the Notes is payable quarterly on March 31, June 30, September 30 and December 31 of each year. The Notes mature
on December 7, 2026 (the “Maturity Date”), and, on the Maturity Date, Schwazze is obligated to pay holders of the Notes $1.00
in cash for each $1.00 principal amount of Notes held, together with accrued and unpaid interest to, but not including the Maturity Date
on such Notes. Schwazze’s obligations under the Notes are secured by (i) a junior security interest in the assets of PBS Holdco
LLC, a wholly-owned subsidiary of Schwazze, Schwazze’s Colorado manufacturing operation, 36 acres of land in Huerfano County, Colorado
owned by Schwazze and substantially all of the assets owned by SBUD LLC, a wholly-owned subsidiary of Schwazze, and (ii) a first priority
security interest in all assets owned by Schwazze and all of its direct or indirect subsidiaries on or after December 7, 2021.
Schwazze is currently in default on its payment
obligations under the Notes. Chicago Atlantic Admin, LLC serves as collateral agent under the Indenture governing the terms of the Notes.
John Mazarakis, the Company’s Chief Executive Officer, is a partner of Chicago Atlantic Group, LP, an affiliate of Chicago Atlantic
Admin, LLC.
The Shares of the Company to be issued by the
Company to the Noteholders will be issued in reliance upon the exemptions from registration under the Securities Act provided by Section
4(a)(2) of the Securities Act as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act.
The information provided herein shall not constitute
an offer to sell or the solicitation of an offer to buy any securities of the Company.
The foregoing description of the Note Purchase
Agreements is only a summary, does not purport to be complete and is qualified in its entirety by reference to the full text of the form
of Note Purchase Agreement, a copy of which is included as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Forward-Looking Statement Disclosure
This Current Report on Form 8-K and the exhibits
hereto contain “forward-looking information” within the meaning of applicable United States and Canadian securities legislation.
Forward-looking information contained in this Current Report on Form 8-K may be identified by the use of words such as “should,”
“believe,” “estimate,” “would,” “looking forward,” “may,” “continue,”
“expect,” “expected,” “will,” “likely,” “subject to,” and variations of such
words and phrases, or any statements or clauses containing verbs in any future tense and includes statements regarding the timing of the
closing of the acquisition of the Notes, if a closing occurs at all. These statements should not be read as guarantees of future performance
or results. Forward-looking information includes both known and unknown risks, uncertainties, and other factors which may cause the actual
results, performance, or achievements of the Company or its subsidiaries to be materially different from any future results, performance,
or achievements expressed or implied by the forward-looking statements or information contained in this press release. Forward-looking
information is based upon a number of estimates and assumptions of management, believed but not certain to be reasonable, in light of
management’s experience and perception of trends, current conditions, and expected developments, as well as other factors relevant
in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment,
and the availability of licenses, approvals and permits.
Although the Company believes that the expectations
and assumptions on which such forward-looking information is based are reasonable, the reader should not place undue reliance on the
forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments
may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties
that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and
uncertainties include, but are not limited to: risks related to the timing and content of adult-use legislation in markets where the
Company currently operates; current and future market conditions, including the market price of the subordinate voting shares of the
Company; risks related to epidemics and pandemics; federal, state, local, and foreign government laws, rules, and regulations, including
federal and state laws and regulations in the United States relating to cannabis operations in the United States and any changes to such
laws or regulations; operational, regulatory and other risks; execution of business strategy; management of growth; difficulties inherent
in forecasting future events; conflicts of interest; risks inherent in an agricultural business; risks inherent in a manufacturing business;
liquidity and the ability of the Company to raise additional financing to continue as a going concern; the Company’s ability to
meet the demand for flower in its various markets; risk of failure in the lawsuit with Verano and the cost of that litigation; our ability
to dispose of our assets held for sale at an acceptable price or at all; and risk factors set out in the Company's Annual Report on Form
10-K for the year ended December 31, 2024, which is available on EDGAR with the SEC and filed with the Canadian securities regulators
and available under the Company's profile on SEDAR+ at www.sedarplus.com.
| Item 9.01. | Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit No. |
|
Description |
| 10.1 |
|
Convertible Note Secondary Sale and Purchase Agreement (Form A) (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed with the SEC on October 8, 2025) |
| |
|
|
| 99.1* |
|
Press Release, dated as of December 19, 2025 |
| |
|
|
| 104 |
|
Cover Page Interactive Data File (embedded within Inline XBRL document) |
*Furnished herewith
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
VIREO GROWTH INC.
(Registrant) |
| |
|
| Date: December 29, 2025 |
By: |
/s/ Tyson Macdonald |
| |
|
Tyson Macdonald |
| |
|
Chief Financial Officer |
